In this episode, we break down Trump's proposed "Most Favored Nation" model for drug pricing, how it ties U.S. prices to international benchmarks, and where it stands legally and politically. We explain what it could mean for AstraZeneca's portfolio and pricing in the U.S., along with potential implementation hurdles and industry pushback.
Get the top 40+ AI Models for $20 at AI Box: https://aibox.ai
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
